Ajay Major, MD, MBA

We found ORR 70 (CR 45%) of bispecifics after CAR-T, with mPFS 8.9 mos and median DOR and OS not reached. Patients with late post-CAR relapse (>6 months) who were treated with CD20 bispecifics had better outcomes. Infections were common, highlighting cumulative immunosuppression. #lymsm

Real-World Analysis Sheds Light on Bispecific Antibody Activity After CAR T in Mantle Cell Lymphoma | OncLive Real-world data suggest CD20 bispecific antibodies show activity after CD19 CAR T in mantle cell lymphoma, though durability of response remains unclear.

Many thanks to @onclive.bsky.social for reviewing our #Tandem26 abstract on outcomes of CD20 bispecifics after CD19 CAR in R/R MCL, an analysis from the CUBIC Consortium. #lymsm #tcellrx
Abstract link: www.astctjournal.org/article/S266...
www.onclive.com/view/real-wo...

Axi-cel can now be used for R/R PCNSL! HT @samyamshon.bsky.social #lymsm #tcellrx

Infx post CD20 bispecifics @bloodadvances.bsky.social
- 122 pts
- 61% ≥1 infx episode; 37% had Grade 3+ infx!!! (lots of CMV)
- 76% cumulative incidence infx at 2 yrs
- 8% G5 infx at 1 year
Important data (more infx than CAR?); need ppx/IVIG strategies. #lymsm
ashpublications.org/bloodadvance...

Hoping I have favor with the kiln deities! #pleasedontbreak #pottery

Elated to be presenting our MAGIC-ONC vascular access appropriateness recommendations in patients with cancer to the @hms-mi.bsky.social consortium today! Be sure to read the full paper published @annalsofim.bsky.social: www.acpjournals.org/doi/10.7326/... #medsky #oncsky cc @davidpaje.bsky.social

CD3xCD20 BsAb CNS lymphoma #ASH25
- 28 pts from CUBIC (22 glofi), 18 active CNSi
- 6-mo PFS/OS 44%/81%
- active CNSi: ORR 56% (CR 33%)
- 67% received combo tx (BTKi, len, IT chemo)
Outcomes with active CNSi similar to trials. Need more pts & longer f/u. #lymsm #tcellrx

CNS relapse of LBCL after CAR-T #ASH25
- 1102 pts R/R LBCL: 79% CAR, 21% CIT
- 1.6% incidence of CNS relapse after CAR (2.2% CIT cohort)
- time from CAR to CNSr 4.7 mo
Corroborates known CAR CNS penetration. Upfront CAR if high CNSr risk? #lymsm #tcellrx

3-year f/u STARGLO #ASH25
- glofi-GemOx: mPFS 14 (v 3 mos), mOS 26 (v 13 mos)
- in 2L: mPFS 20 (vs 5 mos), mOS NR (vs 14 mos)
- 20% G3+ infx AEs in glofi arm
Maybe a PFS plateau on KM curves if you squint... #lymsm #tcellrx

Q-TWIST analysis of CARTITUDE-4 @surbhisidanamd.bsky.social #ASH25: 9-13 month gain of quality-adjusted time w/o symptoms/toxicity as compared to SOC, and this includes time with high-grade ICANS. #mmsm #tcellrx

Patients with poor baseline HRQoL in ALPINE trial still had PFS benefit with zanu (vs ibrutinib). #lymsm #ASH25

Spiritual wellness & QoL PROs in acute leukemia #ASH25
- 30 pts, 27% AYA, 53% AML
- higher spiritual wellness = better QoL across first 30 days of treatment (at baseline & 30 days)
Opportunity to improve QoL/PROs with spiritual support services at diagnosis. #leusm

Time & financial tox work at #ASH25: 66 pts (40 #lymsm, 26 #mmsm) treated with BsAb or CAR-T. ~25% had significant FT at 3 months, and time tox decreased over time. FT & TT both associated with worse QoL & psychological distress.

Glofi+obin 1L HTB FL #ASH25
- 35 pts, 63% FLIPI 3-5
- ORR 100% (CR 88%)
- pretx with 4 doses of obinu: 40% any-grade CRS, all G1 except 1 case of G3
- 31% infx (all G1-2)
- only 7.5 mo F/U: 8-mo PFS 95%
More chemo-free options in 1L FL; need more f/u. #lymsm

Epidemiological data on NLPHL presented at the @ash.hematology.org #ASH25 Annual Meeting. Using a UK-based cancer registry, higher incidence of NLPHL in Black and Asian patients as compared to White patients. 5-year OS and relative survival of >90%. #lymsm #NLPHLsm

More time toxicity work from #ASH25: adults with ALL spent 25% of days over the first year physically interacting with the health care system. Tremendous potential to improve this with novel agents and/or hospital at home care delivery models. #leusm #AYAsm #timetox @ash.hematology.org

Pirto v venetoclax in R/R WM #ASH25
- 91 pts: 64 VEN
- MV model:⬇️PFS w/ ven if TP53mut;⬇️MRR & PFS w/ pirto if CXCR4mut
- no diff in MRR or PFS between pirto & VEN
- transition from BTKi to VEN = 62% IgM rebound (didn't happen w/ pirto)
Genetic-based tx decisions in WM! #lymsm

A time toxicity analysis of CAR-T in NHL by Trotier et al. from #ASH25 (using claims data) found a 1-year median of 52 contact days, very similar to our multicenter study. Very promising that we can use claims data to generate these time toxicity data. #lymsm cc @uduranimd.bsky.social

Comparison of real-world survival outcomes and time toxicity of CAR T-cell versus bispecific antibody therapies in relapsed/refractory follicular lymphoma: A multicenter cohort from 15 US academic ins... AbstractBackgroundChimeric antigen receptor T-cell (CAR-T) and bispecific antibody (BsAb) therapies are both effective for patients with relapsed/refractor

These data support shared decision-making in R/R FL and enable incorporation of patient preferences regarding duration of disease control and time burden of treatment. #lymsm
Abstract here: ashpublications.org/blood/articl...

ASH 2025 Insights: Comparison of Real-World Survival Outcomes and Time Toxicity of CAR T-Cell vs. Bispecific Antibody Therapies in R/R FL - A Multicenter Cohort From 15 US Academic Institutions A video from Ajay Major (as part of 2025 ASH Annual Meeting Insights Hub), posted on Dec 23, 2025.

In our study of real-world survival & time toxicity of CAR-T vs BsAb in R/R FL, we found that CAR-T resulted in superior PFS but more time toxicity, with no difference in OS.
Over first year, 51-64 physical healthcare contact days with CAR-T vs 36-38 with BsAb. #lymsm
www.vumedi.com/video/ash-20...

Why Childhood Cancer Survivors Are at Higher Risk of Colorectal Cancer — and What Their Doctors Can Do About It Ajay Major's research found childhood cancer survivors got subsequent colorectal cancer at younger ages and had high colorectal cancer mortality rates.

CU Cancer Center member Ajay Major (@majorajay.bsky.social), MD, MBA, led a study of more than 25,000 long-term childhood cancer survivors, to learn more about their rates of colorectal cancer and what their doctors can do about it ⬇️
https://bit.ly/3MkDl2t

Also no difference in hours spent at infusion center between IV vs SQ formulations.
Overall, these data are first & largest of patient-reported time burden with different bispecifics in FL & DLBCL, and provide concrete data to better counsel patients as part of shared decision-making. #ASH25 #lymsm

Significantly fewer all-cause visits with mosun in FL and glofi in DLBCL at 1.6 and 0.8 fewer visits, respectively, vs epcor.
50% reduction in hours spent on cancer-related care with mosun & glofi vs epcor (including less time recovering at home). #ASH25 #lymsm

Enrolled 60 patients w/ FL & 60 w/ DLBCL, all actively on BsAb therapies for >1 month. Over 1/4 were non-White, most urban/suburban, majority treated in academic centers. Majority had been on treatment for >4-6 months. #ASH25 #lymsm

At #ASH25, we presented our patient-reported time toxicity study in 120 pts w/ R/R FL & DLBCL on mosun, glofi & epcor. Mosun & glofi w/⬇️all-cause healthcare visits & hours spent on cancer-related care in past 30 days v epcor.
More details in this #thread. #lymsm
www.sciencedirect.com/science/arti...

Announcing my #ASHNewsDaily Golden Globule award picks for @ash.hematology.org #ASH25! I gave my awards to the best (shocker) patient-reported outcomes abstracts, including quality of life studies from trials and in real-world practice. #MajorPROsASH ashpublications.org/ashnewsdaily...

Thanks for all the great memories, my #ASH25 friends! Stay in touch, and looking forward to seeing your new abstracts at #ASH26. cc @ash.hematology.org

Next steps are to perform longitudinal analyses of our PRO data to assess how various types of therapy affect symptom burden & functional/emotional QoL over time.
Congratulations to Dr. Hofmeister on this work and your
@ash.hematology.org #ASH25 Abstract Achievement Award! #lymsm

Our conclusions:
- Patients have severe emotional impairments despite mild CTCL-related symptoms (including early-stage dx & skin-directed tx only).
- Fear of recurrence/progression is a particular concern.
- Psychological wellbeing in CTCL is an unmet need. #ASH25 #lymsm

Additional findings:
- no differences in scores between early & adv-stage CTCL
- systemic tx = worse sx scores (especially pain)
- Medicaid = worse global scores #ASH25 #lymsm